Industry Medical equipment Total equity €23.9 million (2010) Founder Osmo Suovaniemi | Area served Worldwide Founded 1988 | |
 | ||
Products liquid handling equipment CEO Semi Korpela (14 Dec 2011–) Type of business Public (Nasdaq Helsinki: BIOBV.B) | ||
Biohit Oyj is a Finnish company which develops, manufactures, and markets diagnostics products for use in research and health care.
Contents
Summary
Biohit was established in 1988 in Finland by Professor Osmo Suovaniemi (M.D., Ph.D.), previously known as the founder of Labsystems. He stepped down from the CEO position in June 2011, but remains actively involved with the company through positions on several advisory boards. Biohit Oyj is a globally operating Finnish biotechnology company. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare. Mr Semi Korpela was appointed CEO in 2011.
Markets
Biohit's two businesses are acetaldehyde eliminating products and diagnostics. More than 90% of Biohit's sales occur outside Finland
Diagnostic tests
The diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of Helicobacter pylori infection and atrophic gastritis from a blood sample. They are also ideal tools for identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD) and deficiencies of vitamin B12, calcium and iron. In addition to this, Biohit offers Quick tests for the detection of •Lactose intolerance •Helicobacter pylori infection •Celiac disease •Screening of colorectal cancer
Acetaldehyde binding products
Monoclonal antibodies
Biohit also develops and manufactures monoclonal antibodies for research use and use as raw materials for diagnostic industry.
Instruments
Adopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests.
Distribution Network
A network of 40 distributors, including 2 subsidiaries, in more than 40 countries is selling Biohit products.
Research, Development, and Intellectual Property
Biohit spends roughly 30% of net sales on basic research each year and pursues an aggressive patenting strategy.
In 2014 Biohit started studies on migraine and cluster headache prevention with Acetium capsules.